Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. Blood. 2015.
Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant. 2019.
Allogeneic stem cell transplantation for nonmalignant diseases. Curr Opin Hematol. 2016..
Busulfan or thiotepa based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group. Biol Blood Marrow Transplant. 2018.
Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention. Haematologica. 2016;101(5):e214-e215..
Full Donor Chimerism After Allogeneic Hematopoietic Stem Cells Transplant For Myelofibrosis: The Role Of The Conditioning Regimen. Am J Hematol. 2020.
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation. J Obstet Gynaecol. 2016:1-6..
MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014.
Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at two haematological Italian centres. Biol Blood Marrow Transplant. 2019.
Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood. 2014.
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.